Online citations, reference lists, and bibliographies.
← Back to Search

The Clinical Utility Of Liposomal Doxorubicin In Recurrent Ovarian Cancer.

S. Campos, R. Penson, A. Mays, R. Berkowitz, A. Fuller, A. Goodman, U. Matulonis, A. Muzikansky, M. Seiden
Published 2001 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
OBJECTIVES The aim of this study was to determine the efficacy and toxicity of single agent off-protocol, liposomal doxorubicin (Doxil Alza), in consecutive patients with recurrent ovarian cancer and to investigate the influence of HER-2/neu expression on response to liposomal doxorubicin. PATIENTS AND METHODS Retrospective analysis of 72 consecutive patients treated, typically with liposomal doxorubicin 40 mg/m(2) q28 days between January 1997 and December 1998. Results. Twenty-nine patients (40%) had platinum- and taxane-resistant tumors. Nineteen patients (27%) responded with clinical or radiological evidence of response with reduction in CA-125 of >50%. One complete response (CR) and 7 partial responses (PRs) occurred in platinum- and taxane-resistant patients (radiological response (RR) 29%) and 8 PRs occurred in patients with visceral metastases (RR 28%). Time to progression was 5.3 (2.1-12.1) months. Only 7 dose delays (3%) and 20 dose reductions (8%) were necessary in 265 cycles of treatment. Hematological toxicity was generally mild with grade (Gr) > or =III neutropenia in 1 (2%), Gr > or =III thrombocytopenia in 1 (1%), and Gr > or =III anemia in 8 patients (11%). One patient (1%) was admitted with fever and neutropenia. Other toxicity was minimal with Gr > or =III mucositis occurring in 3 patients (4%). Gr > or =III cutaneous toxicity was seen in 6 patients (8%). Three patients (4%) had a >10% fall in ejection fraction but there was no unequivocal clinical heart failure. CONCLUSIONS The data suggest that liposomal doxorubicin is an active drug in both taxane- and platinum-sensitive and resistant recurrent ovarian cancer. Liposomal doxorubicin is associated with tolerable toxicity and is particularly well tolerated in patients with multiple prior lines of treatment.
This paper references
Salvage weekly paclitaxel in recurrent ovarian cancer.
N. Abu-Rustum (1997)
10.1200/JCO.1994.12.1.60
Oral etoposide is active against platinum-resistant epithelial ovarian cancer.
P. Hoskins (1994)
10.1006/GYNO.1997.4787
Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
E. Swisher (1997)
10.1200/JCO.1996.14.5.1545
Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.
G. Rustin (1996)
Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model.
D. Vail (1998)
10.1002/1097-0142(19900215)65:4<870::AID-CNCR2820650407>3.0.CO;2-D
Reduced cardiotoxicity of doxorubicin by a 6‐hour infusion regimen. A prospective randomized evaluation
J. Shapira (1990)
10.1200/JCO.1998.16.5.1849
Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.
M. Markman (1998)
ADVANCED OVARIAN CANCER : RECENT PROGRESS AND CURRENT CHALLENGES
N. Sharpless (1998)
10.1016/s0923-7534(20)31484-8
Gemcitabine in the treatment of ovarian cancer.
S. Hansen (1999)
10.1200/JCO.1998.16.2.405
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
P. Rose (1998)
10.1056/NEJM199405053301802
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.
H. Muss (1994)
10.1016/S0959-8049(96)00446-7
A call for change in anticancer drug evaluation.
E. Cvitkovic (1997)
10.1200/JCO.1997.15.3.987
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
F. Muggia (1997)
10.1126/SCIENCE.2470152
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
D. Slamon (1989)
10.1200/JCO.1997.15.6.2183
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
W. W. ten Bokkel Huinink (1997)
10.1038/380561A0
Doxorubicin in sterically stabilized liposomes
D. Lasic (1996)
10.1002/1097-0142(19940301)73:5<1478::AID-CNCR2820730526>3.0.CO;2-1
Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts
J. Vaage (1994)
10.1002/j.1552-4604.1996.tb04152.x
Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma
D. Northfelt (1996)
10.1200/JCO.1995.13.3.726
Impact of doxorubicin on survival in advanced ovarian cancer.
R. A'hern (1995)
10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
Reporting results of cancer treatment
A. Miller (1981)
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
A. Gabizon (1994)
10.1097/00004347-199401000-00006
Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression.
H. Meden (1994)
10.1038/bjc.1994.33
Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.
M. Seymour (1994)



This paper is referenced by
10.1016/B978-0-443-06694-8.50097-X
Ovaries and Fallopian Tubes
D. Armstrong (2008)
Progressive epithelial ovarian carcinoma
B. Grønlund (2006)
10.1007/s12013-013-9534-7
Gambogic Acid Sensitizes Ovarian Cancer Cells to Doxorubicin Through ROS-Mediated Apoptosis
J. Wang (2013)
Pegylated liposomal doxorubicin in ovarian cancer
A. Green (2006)
10.1517/14656566.7.11.1469
Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary
M. Markman (2006)
10.1159/000112730
Use of Systemic Antineoplastic Drug Therapy after Regulatory Agency Approval
M. Markman (2007)
10.1186/s12885-017-3981-2
Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
R. L. Hollis (2017)
10.1093/ANNONC/MDL484
Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer.
E. Andreopoulou (2007)
10.1159/000312644
High Cumulative Doses of Pegylated Liposomal Doxorubicin Are Not Associated with Cardiac Toxicity in Patients with Gynecologic Malignancies
J. Kesterson (2010)
10.1080/07357900701579562
“Conflict-of-Interest” and Participation in IRB Deliberations: An Alternative Perspective
M. Markman (2008)
10.4137/CMT.S4456
Pegylated Liposomal Doxorubicin in the Management of Ovarian Cancer
G. Ferrandina (2010)
10.4414/FMS.2003.04991
Chimiothérapie du carcinome ovarien
S. Aebi (2003)
10.1200/JCO.2010.29.0866
Reply to M. Markman
G. Ferrandina (2010)
10.1002/cncr.22045
Role of chemotherapy for patients with recurrent platinum‐resistant advanced epithelial ovarian cancer
R. Rocconi (2006)
[Pegylated liposomal doxorubicin in ovarian cancer treatment].
E. Nowak-Markwitz (2009)
10.1016/J.YGYNO.2004.03.024
Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies.
D. Uyar (2004)
10.1016/j.ygyno.2009.03.001
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
D. Gershenson (2009)
10.1053/CTRV.2002.0262
Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer.
J. Stebbing (2002)
10.1088/0957-4484/25/47/475101
Targeting multiple types of tumors using NKG2D-coated iron oxide nanoparticles.
M. Wu (2014)
Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.
B. Grønlund (2006)
10.1007/s00432-003-0497-8
Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer
P. Escobar (2003)
10.1016/S0889-8588(03)00057-1
Salvage therapy for recurrent epithelial ovarian cancer.
V. Baker (2003)
10.1038/sj.bjc.6601501
Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?
B. Grønlund (2004)
10.1016/j.ejca.2016.09.004
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.
C. Marth (2017)
10.1556/OH.2007.28188
[Frequency of blood transfusions for anemia caused by chemotherapy in ovarian cancer patients. Thoughts about the guidelines modified in 2006 for the treatment of anemic cancer patients by the European Organisation for Research and Treatment of Cancer].
O. Lehoczky (2007)
10.5737/1181912X173137140
Efficacité d’un programme de soutien infirmier à l’intention de patientes atteintes d’un cancer de l’ovaire récidivant qui reçoivent un traitement à base de doxorubicine liposomale pégylée (Caelyx®/Doxil®)
N. Grenier (2007)
10.1016/J.YGYNO.2004.02.028
Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies.
R. Penson (2004)
10.1002/cncr.22967
Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice
M. Markman (2007)
10.2147/IJN.S255170
Quantification of Synergistic Effects of Ceragenin CSA-131 Combined with Iron Oxide Magnetic Nanoparticles Against Cancer Cells
Ewelina Piktel (2020)
10.3892/OL.2016.4740
Non-pegylated liposomal doxorubicin for patients with recurrent ovarian cancer: A multicentric phase II trial.
J. Brucker (2016)
10.2165/00003495-200868060-00004
Pharmaceutical Management of Ovarian Cancer
M. Markman (2012)
10.1097/00001813-200207000-00009
Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer
F. Di Nicolantonio (2002)
See more
Semantic Scholar Logo Some data provided by SemanticScholar